EyeTechCare

What EyeTechCare does

EyeTechCare (legally EYETECHCARE) is a privately held French medical technology company founded in 2008 and headquartered in Rillieux-la-Pape, France. It develops and manufactures the EyeOP1® system, a CE-marked Class IIb medical device that uses High-Intensity Focused Ultrasound (HIFU) to deliver Ultrasound Cyclo Plasty (UCP), a non-invasive treatment that thermally coagulates the ciliary body to lower intraocular pressure in glaucoma patients. The platform includes the EyeOP1 therapy module with touchscreen parameter control and the EyeOP-PACK range of treatment cones/probes in 11, 12, and 13mm diameters, with UCP Flex extending the offering to dose-customizable protocols.

The company sells hardware and consumables to eye hospitals and clinics worldwide, reaching more than 10,000 patients cumulatively across Europe, Asia, and EMEA regions via a global network of distribution partners rather than a large direct sales force; it also holds independent China NMPA approval obtained in 2017. Revenue mechanics are quote-based institutional sales of the device plus recurring probe consumables, with the founder-controlled structure (co-founders Laurent Farcy, Fabrice Romano, and Philippe Chapuis) still intact and operating leadership under CEO Dietrich Wolf, who joined in 2014 from Carl Zeiss Meditec. The company has raised approximately $40M across disclosed rounds in 2013 (Omnes Capital, Sham) and 2016 (Everpine Capital), supporting commercialization and regulatory expansion.

Customer concentration is channel-mediated rather than direct: end users are leading ophthalmology centers including Hôpital Universitaire de Grenoble, Hôpital de la Croix-rousse Lyon, Hôpital Universitaire de Lille, Sun Yat-Sen University Guangzhou, Eye & ENT Hospital Fudan University Shanghai, and University of Bologna. Clinically, the technology reports 70–80% success rates at 12–18 months and 30–35% average IOP reduction at 12 months, positioning EyeTechCare's offering against invasive surgical alternatives in the rapidly growing global glaucoma burden (75 million patients today, 112 million projected by 2040).

Name

EyeTechCare

Legal name

EYETECHCARE

Website

https://eyetechcare.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

EyeTechCare is a French medical device company that develops and markets the EyeOP1 system, a CE-marked ultrasound-based, non-invasive treatment for glaucoma, sold globally through distribution partners to ophthalmology hospitals and clinics.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

Keywords

• Glaucoma treatment devices
• Focused ultrasound therapy
• Ophthalmic medical devices
• Non-invasive eye surgery
• Cyclo-plasty procedures

Headquarters

HQ city

Rillieux

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. EyeOP1 Medical Device Sales: Sale of the EyeOP1 therapy module and consumable treatment cones/probes to eye hospitals and clinics. The device is CE-marked (Class IIb) and approved for glaucoma treatment using focused ultrasound technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

EyeTechCare develops and manufactures the EyeOP1®, a Class IIb medical device that delivers Ultrasound Cyclo Plasty (UCP), a non-invasive glaucoma treatment using High-Intensity Focused Ultrasound (HIFU). The system consists of the EyeOP1 therapy module plus consumable EyeOP-PACK treatment cones/probes in three sizes, and reduces intraocular pressure (IOP) through thermal coagulation of the ciliary body in a 5-minute repeatable procedure. The company sells devices and consumables directly and through distribution partners to eye hospitals, clinics, and academic medical centers worldwide.

Product overview

EyeTechCare offers a unified medical device ecosystem centered on its EyeOP1® system, which delivers UCP (Ultrasound Cyclo Plasty) — a non-invasive glaucoma treatment using High-Intensity Focused Ultrasound. The core EyeOP1® therapy module works in conjunction with EyeOP-PACK probes (available in three sizes) to coagulate the ciliary body and reduce intraocular pressure. UCP Flex extends the technology by enabling dose customization. The company positions its technology as an alternative to invasive surgical procedures, with treatments that are fast (5 minutes), repeatable, and non-invasive.

Differentiator

Problem solved

Functional benefit

Brands

• EyeOP1: Class IIb medical device using high-intensity focused ultrasound for glaucoma treatment
• EYEOP-PACK
• UCP Flex

Products and services

• EyeOP1® Therapy Module The EyeOP1® is a Class IIb medical device with CE marking No. 0459 that generates focused ultrasound for non-invasive glaucoma treatment via Ultrasound Cyclo Plasty (UCP). It is a compact, ergonomic therapy module with a touchscreen interface for parameter control and procedure monitoring. It is sold to eye hospitals, clinics, and academic medical centers worldwide for the treatment of refractory glaucoma by reducing intraocular pressure (IOP) without surgical incision.
• EyeOP-PACK Treatment Probes EyeOP-PACK is the treatment probe and cone positioning system used with the EyeOP1 device, available in three sizes (11, 12, and 13 mm diameter) selected based on White-to-White and Axial Length measurements to fit patient ocular anatomy. It is a recurring consumable sale to EyeOP1 customers for each glaucoma treatment performed.
• UCP Flex (Adjustable-dose treatment protocol) UCP Flex is an adapted variant of the UCP (Ultrasound Cyclo Plasty) treatment protocol that allows physicians to adjust the ultrasound dose delivered to patients based on individual needs, expanding the range of treatable glaucoma types and patient populations. It is offered to EyeOP1 customers as a configurable treatment protocol enabled by firmware/software on the EyeOP1 device.

Quantifiable outcome

• 30-35% average IOP reduction at 12 months
• +4 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Distribution PartnerscoreChannel Partner/ Reseller/ DistributorGlobal network of distribution partners responsible for selling and supporting UCP technology in various regions worldwide. Partners are dedicated to making focused ultrasound treatment accessible to glaucoma patients in their markets.
• InfluactiveminorOthersDigital agency responsible for website design, development, and hosting services for eyetechcare.com. Located in Lyon, France.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Glaukos Corporation: Glaukos is a leading MIGS (minimally invasive glaucoma surgery) device company. It is directly comparable because it targets the same ophthalmologist/patient base for glaucoma treatment with a device-based alternative to traditional surgery, although its approach is interventional rather than non-invasive.
• Iridex Corporation: Iridex develops ophthalmic laser systems, including laser probes used for glaucoma cyclophotocoagulation. It competes with EyeTechCare for the same refractory-glaucoma treatment slots, using a different energy modality (laser vs. focused ultrasound).
• Quantel Medical (Ellex): Quantel Medical (combining the legacy Ellex ophthalmic laser business) makes ophthalmic lasers used for glaucoma, including SLT and cyclophotocoagulation. It targets the same ophthalmologist customer base with a non-incisional device alternative to EyeOP1's HIFU approach.

Broad incumbents

• Alcon: Alcon is the largest dedicated ophthalmic company globally, with broad portfolios in surgical, vision care, and pharmaceuticals, including MIGS and glaucoma drugs. It is comparable as the dominant incumbent in the same end market, with vastly greater commercial reach.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic device leader across diagnostics, surgical, and laser platforms, and is also the prior employer of EyeTechCare's CEO. It is comparable as a broad incumbent that overlaps in ophthalmic surgical and diagnostic capital equipment for the same clinical specialties.
• Bausch + Lomb (Bausch Health): Bausch + Lomb is a major global ophthalmic company spanning pharmaceuticals, surgical devices, and contact lenses, including glaucoma therapeutics. It competes with EyeTechCare across multiple ophthalmic care touchpoints and serves the same end-customer base.
• Santen Pharmaceutical: Santen is a Japan-based specialty ophthalmic company with a strong glaucoma pharmaceutical franchise. It is comparable because it serves the same patient population via a different (pharmaceutical) treatment modality and competes for the same ophthalmologist prescribing decisions.
• Nidek: Nidek is a Japanese manufacturer of ophthalmic diagnostic, surgical, and laser devices, including systems used in glaucoma management. It is comparable as a broad ophthalmic device incumbent with overlapping capital equipment offerings to EyeTechCare's installed-base customer type.

Emerging players

• New World Medical: New World Medical develops ophthalmic surgical devices, including devices for glaucoma and other anterior segment conditions. It is comparable as a focused, privately held ophthalmic device company pursuing surgical and procedural alternatives in the same end market.

Others

• Heidelberg Engineering: Heidelberg Engineering specializes in ophthalmic diagnostic imaging (e.g., OCT, HRT) used in glaucoma diagnosis and monitoring. It is adjacent rather than directly competitive, providing complementary tools that support glaucoma specialists who may also adopt EyeTechCare's UCP therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eyetechcare

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EyeTechCare